AlphaStar Capital Management 13F: Adds $601K to ABBV Stake
Key Points
- AlphaStar Capital Management increased its AbbVie Inc. holdings by 13.5%, ending the period with 19,380 shares valued at approximately $5.06 million.
- AbbVie Inc. posted trailing-twelve-month revenue of $64.38 billion alongside earnings of $3.54 per share ahead of its next earnings update on October 30, 2026.
- Wall Street analysts currently maintain a buy consensus on AbbVie Inc. shares with a mean price target of $282.61.
Since the filing, $ABBV is down 1.0% to date (from the $285.42 close on Oct 16, 2026).
Get AbbVie text alerts
We text you when insiders, Congress, analysts or big funds move on $ABBV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
AlphaStar Capital Management grew its stake in AbbVie Inc. ABBV by 13.5% during the quarter, according to a Form 13F filed with the SEC on October 16, 2026.
ABBV
AbbVie Inc.
AlphaStar Capital Management vs. the S&P 500
Hypothetical returns from AlphaStar Capital Management's disclosed trades, not real profit or advice. How we model this.
What Changed in AlphaStar Capital Management's AbbVie Inc. Position
The firm added 2,299 shares of the drug maker during the period, bringing its total holdings to 19,380 shares. The updated stake was valued at approximately $5,069,641 at the close of the quarter, up from its previous holdings of 17,081 shares.
Other Institutional Activity in AbbVie Inc.
Other major institutional investors adjusted their positions in the pharmaceutical giant during the same filing window. Y-Intercept completely exited its position in AbbVie Inc., selling off 74,248 shares to bring its holdings down to zero shares worth $0.
AbbVie Inc. Stock Down 1.0%
AbbVie Inc. shares recently traded around $282.68 as of October 20, 2026, sitting roughly 1.0% below the $285.42 close recorded on the October 16 filing date. The stock trades above both its 50-day moving average of $262.45 and its 200-day moving average of $233.95.
Recent Earnings
AbbVie Inc. reported trailing-twelve-month revenue of $64.38 billion and earnings of $3.54 per share. The company posted a net profit margin of 9.8% and year-over-year revenue growth of 10.2%. Investors look ahead to the company's next earnings report, scheduled for release on October 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
AbbVie Inc. pays an annual dividend rate of $6.92 per share, translating to a dividend yield of 2.45%. The company maintains a dividend payout ratio of 190.4%.
Insider Buying and Selling at AbbVie Inc.
Company insiders completed several stock transactions earlier in the year. General Counsel Perry C. Siatis sold 22,381 shares at $230.00 on February 25, 2026, for a total value of $5,147,630, followed by another sale of 18,668 shares valued at $4,375,549 on March 2, 2026. Officer David Ryan Purdue sold 5,230 shares at $233.56 on March 4, 2026, totaling $1,221,519. Later, officer Nicholas Donoghoe sold 32,710 shares at $250.00 on August 14, 2026, worth $8,177,500.
Analysts Set New Price Targets
Wall Street research firms issued updated views on the stock leading up to the filing. JP Morgan maintained an overweight rating on October 8, 2026, while lifting its price target from $285.00 to $300.00. Cantor Fitzgerald also maintained an overweight rating on October 8, 2026, raising its price target to $290.00 from $285.00. UBS maintained a neutral rating on October 9, 2026, moving its price target from $260.00 to $275.00. Guggenheim reiterated a buy rating with a $288.00 target on October 9, 2026, and RBC Capital reiterated an outperform rating with a $280.00 target on October 13, 2026. AbbVie holds a consensus buy rating from 28 analysts with a mean price target of $282.61.
About AbbVie Inc.
AbbVie Inc. operates as a research-driven biopharmaceutical enterprise that discovers, develops, and markets therapeutic medicines globally. The company focuses on specialized treatments for immunology, oncology, and neuroscience, offering widely used therapies such as Skyrizi, Rinvoq, and Imbruvica.
Bottom Line
Institutional interest in AbbVie remains active as the company heads toward its upcoming earnings report on October 30, 2026. Market participants will watch for further updates on drug sales and institutional portfolio adjustments in subsequent SEC filings.
Related Filing Alerts
Source: AlphaStar Capital Management's 13F filing on $ABBV (Oct 16, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts